 Nes-Ziona, Israel, Nov. 05, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods of using AllocetraTM, the companys immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohns disease, and ulcerative colitis. The company expects that this new patent will be issued in the United States in the coming months. 